| MHC Biologics seeks commercialization partners to capitalize on this unique antibody therapeutic opportunity in both oncology and infectious disease applications. The technology is protected by robust intellectual property and strategic patent filings covering the disease-specific epitopes recognized and the TCRm antibody modalities themselves. Together, these technologies are a powerful tool set for diagnosing and treating specific diseases. |
